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To report the prevalence of anti-neuronal antibodies in a prospectively whole nation cohort 
of children presenting with seizures before their third birthday. 
Methods:  
This was a prospective population-based national cohort study involving all children 
presenting with new onset epilepsy or complex febrile seizures before their 3rd birthday 
over a three-year period. Patients with previously identified structural, metabolic or 
infectious cause for seizures were excluded. Serum samples were obtained at first 
presentation and tested for seven neuronal antibodies using live cell-based assays. Clinical 
data were collected using structured proformas at recruitment, and 24 months after 
presentation. In addition, patients with seizures and clinically suspected autoimmune 
encephalitis were independently identified by reviewing the case records of all children < 3 
years in Scotland who had undergone electroencephalography (EEG). 
Results: 298 patients were identified, recruited and underwent autoantibody testing. 
Antibody positivity was identified in 18/298 (6.0%). The antibodies identified were: GABABR 
(n = 8, 2.7%), CASPR2 (n = 4, 1.3%), GlyR (n = 3, 1.0%), LGI1 (n = 2, 0.7%), NMDAR (n = 1, 
0.3%), and GABAAR (n = 1, 0.3%). None of these patients had a clinical picture of 
autoimmune encephalitis. Seizure classification and clinical phenotype did not correlate 
with antibody positivity.  
Conclusions: Autoimmune encephalitis is very rare in early childhood. However serum 
neuronal antibodies are identified in 6.4% of children presenting with seizures < 3 years.  
Antibody testing should not be a routine clinical test in early childhood-onset epilepsy as in 
the absence of other features of autoimmune encephalitis antibody-positivity is of doubtful 
clinical significance. Antibody testing should be reserved for patients with additional 





Autoimmune encephalitis encompasses a constellation of acquired immune mediated 
conditions in which acute or subacute central nervous system dysfunction is associated with 
a proven or suspected autoimmune process. The ability to identify circulating antibodies 
directed against synaptic epitopes is a major aid to clinical diagnosis. Recent advances in the 
identification and detection of antibodies have allowed the characterisation of a number of 
autoimmune neurological syndromes in adults, about half of which are most commonly 
paraneoplastic in nature1. Some neuronal antibody encephalitides are associated with 
distinct phenotypic features, such as the faciobrachial dystonic seizures in LGI1-antibody 
disease2, but for the majority of antibody-associated encephalitides overlapping phenotypic 
spectra are observed. The most common clinical features are seizures, working memory 
deficits, psychiatric symptoms, and encephalopathy, with movement disorders frequent in 
NMDAR-antibody encephalitis. Typical limbic encephalitis is associated with bilateral signal 
changes within the temporal lobes on MRI T2-weighted FLAIR and CSF pleocytosis, though 
both can be normal in a substantial minority of patients3. 
Autoimmune encephalitis is well described in the paediatric population4. 40% of patients 
with NMDAR-antibody encephalitis are < 18 years old5, with the incidence of this specific 
autoimmune encephalitis estimated at 0.85 per million children per year in the UK6.  There 
have been reports of children as young as eight months presenting with NMDAR 
encephalitis7 and reports of children as young as 20 months benefiting from 
immunomodulating therapy8. Good quality paediatric epidemiological data for encephalitis 
associated with other neuronal antibodies is lacking, and antibody-defined causes appear 
very rare.  
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Rapid identification of antibodies may facilitate early initiation of specific therapy, which 
may in turn improve outcomes. De Bruijn et al. studied a cohort of 110 adult patients with 
seizures associated with autoimmune encephalitis. 14% achieved seizure-freedom whilst 
receiving only antiepileptic drugs (AEDs) yet 53% achieved seizure-freedom shortly after 
commencing immunotherapy9. 
Epileptic seizures are an early clinical feature for the majority of children presenting with 
antibody-associated encephalitis10. Since children presenting for the first time with epileptic 
seizures are likely to present to hospital, screening of such children for neuronal antibodies 
presents a good opportunity to identify autoimmune encephalitis early.  
Methods 
Participants were recruited from all 20 regional paediatric departments and four tertiary 
children’s hospitals in Scotland, from May 8th 2014 to May 7th 2017. Only children who met 
the inclusion criteria during this time period, and who were under 36 months of age, were 
included. The same cohort underwent genetic testing using a gene panel of 104 genes11. 
Inclusion criteria: any of: i) child receiving a new diagnosis of epilepsy (recurrent 
unprovoked seizures); ii) child presenting with an episode of febrile or afebrile status 
epilepticus (seizure >30 minutes); iii) child presenting with two or more febrile or afebrile 
epileptic seizures within a 24-hour period; iv) child presenting with a second prolonged (>10 
minutes) febrile seizure. 
Exclusion criteria: Patients were excluded if an aetiology that would fully explain seizures 
was already established prior to or at first presentation with seizures. Patients were not 
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excluded if an aetiology was subsequently identified, for example through imaging or 
genetic testing. 
Maximum case ascertainment was ensured by weekly email reminders throughout the 
study period to the eight paediatric neurophysiology departments, a link clinician in each of 
the 24 centres and all 17 epilepsy specialist nurses in Scotland. Research nurses throughout 
Scotland reviewed admissions to intensive care and high dependency units. A national 
continuing education program maintained the profile of the study. 
Autoantibody testing 
Serum samples were tested at the University of Oxford using live cell-based assays for 
antibodies to  leucine rich glioma inactivated 1 (LGI1), contactin-associated protein 2 
(CASPR2), gamma-amino butyric acid receptors A and B (GABAAR, GABABR), N-Methyl-D-
aspartic acid receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR), and glycine receptor (GlyR).  Cut-off values for considering positive were 
a clear signal at the following dilutions: LGI1 (1:100), CASPR2 (1:100), GABAAR (1:100), 
GABABR (1:50), NMDAR (1:50), AMPAR (1:50), GlyR (1:100). Methods for these antibody 
tests have been reported previously12. 
Clinical information  
At the time of case recruitment, clinicians completed a structured proforma detailing clinical 
features and investigation findings (Supplement A). All proformas were reviewed by a panel 
of three paediatric neurologists (SMZ, AM, MK) to ensure that eligibility criteria had been 
met. The clinician recruiting each participant was contacted 24 months after recruitment for 
a diagnostic update. This update specifically enquired as to whether the patient had a 
diagnosis of epilepsy; how the epilepsy diagnosis was classified according to the 
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recommendations of the 2017 position paper of the International League Against Epilepsy 
(ILAE)13; whether a diagnosis of drug-resistant epilepsy (DRE) had been made; and whether 
the child satisfied a diagnosis of global developmental delay (GDD). DRE was defined as a 
child continuing to have seizures (at least one pre six months) despite two adequately 
trialled and tolerated anti-epileptic drug (AED) regimens. GDD was defined as a 
developmental attainment at least two standard deviations below the mean for age in at 
least two different domains of development (gross motor, fine motor, speech and language, 
or social). 
As a separate study the same cohort of patients underwent genetic testing, involving a 104 
gene panel11. Gene panel testing identified a causative genetic variant in 24% of patients, 
with the most commonly-implicated genes being PRRT2, SCN1A, KCNQ2, and SCL2A1. 
Genetic diagnosis was significantly associated with early age of onset, presentation with 
afebrile focal seizures, and with development of both drug-resistance and developmental 
impairment at 2-year follow-up. 
Further biochemical, genetic and neuroradiological investigations, including lumbar 
puncture, chromosomal microarray, directed single gene sequencing, whole genome 
sequencing, and MRI neuroimaging were requested at the discretion of the recruiting 
clinician and these results were available to them as per usual clinical practice. The 
recruiting clinician was blinded to the results of antibody testing, unless they had also 
requested antibody testing on a clinical basis. 
Clinical case identification 
To determine if there were any children with clinically diagnosed with autoimmune 
encephalitis presenting during the study period who were not recruited to the prospective 
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study we reviewed the case records of all children who had undergone EEG investigation 
across the eight paediatric EEG departments in Scotland. The case records of all children 
who underwent EEG between January 1st 2014 and December 31st 2017 and who were 
under 48 months of age were reviewed (total number = 2,396). Children who were over 36 
months of age at presentation and children who presented before May 8th 2014 or after 
May 7th 2017 were excluded. 
Blinded neuroimaging review 
Additional review of MRI neuroimaging was undertaken by a neuroradiologist (KF) who was 
blinded to the antibody findings in each case. MRI scans of all patients with antibody 
positivity who had undergone MRI, and an equal number of closely age-matched patients 
from this cohort without positive neuronal antibodies were reviewed systematically. Images 
were scored according to the presence or absence of features suggestive of autoimmune 
encephalitis (Supplement B). 
Population data 
Denominator data for the <3 years population in Scotland during the study period were 
taken from National Records of Scotland birth records14. The figures were as follows: 2014 – 
172,570; 2015 – 170,492; 2016 – 169,265. The sum of these figures comes to 512,237 
person-years. 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study was approved by the United Kingdom NHS National Research Ethics Service. 
Signed parental consent for immunological testing, and for questionnaire-based follow-up, 
was obtained for each participant in the prospective study. 
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Role of the Funding Sources 
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
Data Availability 
Following publication of this manuscript all anonymised data upon which this study is based 
will be deposited and freely available on the University of Glasgow Enlighten Research Data 
Repository, available at http://researchdata.gla.ac.uk/ 
Results 
298 participants were recruited, underwent testing for seven neuronal antibodies, and were 
followed up for 24 months.  
At 24 months post-presentation, 228 (76.5%) of participants had a diagnosis of epilepsy, 87 
(29.2%) had a diagnosis of GDD, and 63 (21.1%) had DRE. Epilepsy classification for all 
participants, 24 months after presentation, is shown in Table 1. The full spectrum of early 
childhood epilepsies is represented in this cohort. For the majority, a precise epilepsy 
syndrome classification could not be achieved. 
None of the patients recruited to the prospective study was deemed to have encephalitis 
clinically. Nevertheless, neuronal antibodies were identified in serum of 18 (6.0%) of 
patients (Figure 1), including one who was positive for both NMDAR- and GABABR-
antibodies. Age-related control data using these live assays are not available, and the only 
systematic study of asymptomatic adults used the commercially-available fixed assays15. 
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GABABR-antibodies were more common in this cohort (8/228, 2.7%) than in that study 
(0.2%).    
The epilepsy syndromes diagnosed in each of the 18 individuals with positive antibodies are 
shown in Table 2. The antibodies were not associated with any of the clinical presentations 
(Supplement C). The ages at presentation of the antibody positive patients were evenly 
distributed throughout the three years (Supplement D).  
Nine (47%) of the 18 antibody-positive patients also have genetic diagnoses. One patient, 
with a paternally inherited duplication of the KCNQ2 gene (44kb duplication at 20q13.33) 
also had LGI1 antibodies. This patient came from a family with a dominant family history of 
self-limited infantile seizures. Benign familial neonatal seizures is a typical phenotype in this 
duplication syndrome16, though in this family seizure onset was later at between three and 
six months of age. The patient began having seizures at four months of age. Unlike in the 
other affected family members, seizures were drug-resistant and were associated with 
severe global developmental delay and cerebral visual impairment. At 34 months of age the 
patient was functioning at six month level for gross motor, fine motor, visual and social 
skills, and at eight month level for speech and language.  
242 patients had neuroimaging, of whom 218 had MRI and 24 had CT only. Out of the 242 
patients who had MRI (n=218) or CT (n=24), 17 patients had a structural aetiology identified. 
Of these, none was antibody-positive. On blinded review of the MRI brain scans of all 11 
antibody-positive patients who had had MRI and 11 age-matched antibody-negative 
patients, none showed radiological features of encephalitis. Seven of the antibody-positive 
patients underwent diagnostic lumbar puncture at the time of their initial presentation. In 
all seven cases the CSF cell count, protein, and glucose were in the normal range for age. 
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From the retrospective EEG/case note review only one patient with autoimmune 
encephalitis was identified, and this was secondary to viral encephalitis. This individual 
presented at 21 months of age with focal seizures and encephalopathy. Herpes Simplex 
Virus (HSV) was isolated from his cerebrospinal fluid (CSF). This patient was not recruited to 
the prospective study since an aetiology had been identified. Herpes simplex encephalitis 
was associated with a destructive brain lesion with bilateral perisylvian cortical and 
subcortical abnormalities on MRI and subsequent cortical atrophy. At first presentation 
NMDAR antibodies were tested and were negative. Four weeks later the patient developed 
a hyperkinetic movement disorder. Both serum and CSF tested positive for NMDAR 
antibodies. Secondary NMDAR encephalitis following HSV encephalitis is a recognised 
association17,18. 
Discussion: 
Autoimmune encephalitides are rare conditions3. In this prospective population-based 
cohort study we have shown that in children < 3 years of age, these are extremely rare. 
Nevertheless, 6% of the patients had positive serum neuronal antibodies which did not 
associate with any of the clinical features studied. Additionally blinded review of the MRI 
brain scans of 11 antibody-positive patients and 11 age-matched antibody-negative patients 
showed no radiological features of encephalitis. 
Only one patient <3 years presented in Scotland with clinically suspected autoimmune 
encephalitis over the three-year period of this study, and this was secondary to Herpes 
simplex encephalitis17,18.  This equates to an incidence of autoimmune encephalitis in this 
age group of 0.19 per 100,000 person-years. Given the wide confidence intervals from a 
small study population, this figure is not very different from the 0.085 per 100,000 person-
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years for all paediatric NMDAR encephalitis, estimated from a UK prospective surveillance 
study which included patients aged 0-17 years6. 
There is a well-established link between autoimmune disease (AD) and epilepsy. One in five 
people with epilepsy has a co-morbid AD. This link appears to be stronger with paediatric-
onset disease. In a study evaluating insurance records of >2.5 million individuals in the 
United States, the odds ratio for a diagnosis of epilepsy was 3.8 (95% CI, 3.6-4.0) in patients 
who had one or more of the following autoimmune diseases: type 1 diabetes mellitus, 
psoriasis, rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, Crohn disease, 
ulcerative colitis, systemic lupus erythematosus, antiphospholipid syndrome, Sjogren 
syndrome, myasthenia gravis, coeliac disease. In the < 18 years age group the odds ratio was 
5.2 (95% CI, 4.1-6.5). A temporal association between AD and epilepsy has also been 
observed, with most patients experiencing seizure onset within the first two years of AD 
diagnosis. This observation lends support to the hypothesis that seizures in these patients 
may be a direct result of an autoimmune process, as opposed to reflecting a shared genetic 
predisposition19. 
When adults presenting with seizures are tested for neuronal antibodies in serum, the 
presence of these antibodies is usually associated with features of autoimmune 
encephalitis, including history of viral prodrome, neuropsychiatric changes, autonomic 
instability, and medial temporal sclerosis on MRI20. Antibody-positive adults with epilepsy 
are less likely to respond to conventional anti-epileptic medication, and more likely to 
respond to immunomodulating treatments20,21. 
Unlike in adults, when cohorts of children with epilepsy are tested for serum neuronal 
antibodies, associations with clinical features of encephalitis and with drug-resistance are 
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less clear. Earlier studies, several before the discovery of neuronal surface antibodies as we 
examined here, measured VGKC-complex antibodies, which can target intracellular 
epitopes, and GAD antibodies which always target the intracellular enzyme22; both of these 
are relatively common in epilepsy patients but are unlikely to be directly pathogenic.  
Wright et al. retrospectively analysed the serum of 178 patients recruited to the Dutch 
Study of Epilepsy in Childhood (DESC). They tested for antibodies to NMDAR, CASPR2 and 
contactin-2. Overall 14 patients (7.7%) were antibody positive. The antibody positive 
patients did not differ from the antibody negative patients in terms of seizure types, age of 
onset, seizure frequency or AED response. Wright and colleagues also noted that, despite 
not receiving specific treatment, the majority of patients with antibody positivity became 
antibody negative over time, whilst others developed antibodies at a later stage23. Borusiak 
et al. screened for serum GAD65, VGKC, LGI1 and CASPR2 antibodies in 124 children who 
were seen in a single epilepsy centre and diagnosed with focal epilepsy. 5/124 (5%) were 
antibody positive, and none of these were thought to have features characteristic of 
autoimmune encephalitis24. 
Thus the findings from our prospective population-based study support the conclusion that 
antibody positivity in children presenting with seizures is usually non-specific, and is rarely 
associated with a clinical picture of encephalitis. There are several specific strengths to this 
cohort. First, it includes more children than previous paediatric cohorts. Second, there was 
minimal selection bias since all children presenting with seizures in Scotland over a three-
year period were eligible. Third, we tested a wider array of antibodies than previous 
paediatric cohorts. Finally, this cohort was extensively investigated for other aetiologies, 
most notably though genetic testing, with 281/298 (94.3%) being tested on a 104 gene 
epilepsy panel. Comprehensive investigation for alternative aetiologies allowed us to 
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compare differences in antibody positivity between those with and without confirmed 
aetiologies. There were no significant differences observed. Antibody positivity was found in 
5/69 (7.2%) patients with a genetic cause, and in 14/229 (6.1%) patients without a genetic 
cause. Whilst this clearly supports the notion that neuronal antibodies are unlikely to be 
sufficient to cause epilepsy in this age group on their own, it does not exclude the possibility 
that they may be part of a more complex multi-factorial picture. Indeed in the case of one 
patient with both genetic KCNQ2 duplication and LGI1 positivity, it is possible that a genetic 
potassium channel disease had somehow initiated an antibody response to LGI1, which is 
part of a potassium channel complex; alternatively, the spontaneous presence of LGI1 
antibodies may have modified expression of the genetic disorder. 
The only antibody that was more prevalent in this cohort than in healthy adult control 
populations was GABABR. This antibody is associated with adult-onset limbic encephalitis, a 
condition characterised by behavioural and cognitive changes and prominent seizures which 
are often prolonged. Two thirds of adult patients affected by GABABR encephalitis have a 
tumour, most commonly non-small cell lung cancer25. The significance of GABABR 
antibodies in this <3 years paediatric epilepsy group is unclear, but is worthy of further 
investigation, particularly since all of those with GABABR positivity presented in the first 18 
months of life. However, as with the other patients with antibody positivity, those with 
GABABR positivity presented with a variety of clinical phenotypes not suggestive of 
encephalitis and included patients with a confirmed genetic cause for their epilepsy (1 Wolf-
Hirschhorn, 1 PRRT2, 1 ALG3). We identified four patients with CASPR2 antibodies and two 
with LGI antibodies. Autoimmune syndromes associated with these potassium channel 
antibodies have previously been reported in children as young as two years, but in these 
cases seizures are typically associated with encephalopathy, behavioural changes, and/or 
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dyskinesia26. Three patients in our cohort had GlyR antibodies. GlyR associated disease also 
been reported to affect children as young as one year, albeit very rarely. These patients 






• The prevalence of positive neuronal antibodies in healthy young children without 
epilepsy is not known. We relied on published data from adult healthy controls. 
• In the majority of patients only serum samples were tested. Testing for antibodies in 
the CSF may only be appropriate if lumbar puncture is clinically indicated. 
• Samples were only tested at initial presentation with seizures. Repeat testing over a 
period of time may determine the natural course of antibody positivity. 
• This study only included children under three years of age, an age group not typically 
thought to be high risk for autoimmune encephalitis. 
• In young infants IgG antibodies may be transplacentally transmitted from the 
mother. We did not test mothers in this cohort for antibodies. 
• The current study was limited to the common neuronal antibodies and did not test 
for other rarer encephalitis-associated neuronal antibodies  
• Future follow up studies of these patients is needed to establish the natural course 
and the relationship between antibody-positivity and later development of 
autoimmune neurological syndromes 
Conclusions: 
A small proportion of children presenting with seizures in the first 36 months of life have 
circulating neuronal antibodies. In only a very small fraction of cases are these associated 
with a clinical picture of autoimmune encephalitis. The significance of antibody positivity in 
those without encephalitis is unclear but these are unlikely to provide an aetiological 
explanation for the epilepsy. We do not recommend routine testing for neuronal antibodies 




Figure 1:  19 positive cell-based assays in 18 patients.  Dilution is that used in the assays; 





Table 1 – Epilepsy syndrome classification 24 months after initial presentation 
Epilepsy syndrome Number 
Developmental and epileptic encephalopathies (DEE), n = 41 
West syndrome 22 
Dravet Syndrome 10 
Early infantile-onset* DEE, including Ohtahara syndrome, Early Myoclonic 
Encephalopathy (EME), and Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) 
*onset at < 4 months of age 
9 
Self-limited epilepsies,  n = 24 
Self-limited familial neonatal epilepsy 4 
Self-limited non-familial neonatal epilepsy 3 
Self-limited familial infantile epilepsy 3 
Self-limited non-familial infantile epilepsy 10 
Myoclonic epilepsy of infancy 4 
Other specific syndromes, n = 35 
Febrile seizures plus 13 
Epilepsy with myoclonic atonic seizures 10 
Early onset absence epilepsy 7 
Epilepsy with myoclonic absences 1 
Absences with eyelid myoclonia 1 
Glut1-deficiency syndrome 1 
Infantile spasms without hypsarrhythmia 1 
Panayioutopoulos syndrome 1 
Unclassified epilepsies,  n = 128 
Unclassified focal epilepsy 52 
Unclassified generalised epilepsy 13 
Unclassified focal and generalised epilepsy 10 
Unclassified myoclonic epilepsy 5 
Unclassified epilepsy 48 
Not epilepsy, n = 70 
Single episode of afebrile status epilepticus (>30 mins) 5 
Single cluster of afebrile seizures (2 or more in 24 hours) 7 
Febrile status epilepticus (>30 mins) 33 
Cluster(s) of febrile seizures (2 or more in 24 hours) 16 
Recurrent prolonged (> 10 mins) febrile seizures 9 
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Table 2 – epilepsy syndromes diagnosed in patients with positive antibody findings 
Antibody      
CASPR 2 Total number 4  
 Syndrome classification  
Unclassified focal epilepsy 2  
Unclassified epilepsy 1  
West syndrome 1  
LGI1 Total number 2  
 Syndrome classification  
Other early infantile-onset DEE 1ϯ ϯ Had causative KCNQ2 gene variant 
Unclassified epilepsy 1  
GABAAR Total number 1  
 Syndrome classification  
Single cluster of febrile seizures 1  
GABABR Total number 8  
 Syndrome classification  
Unclassified epilepsy 2ψ ψ 1 Also positive for NMDAR and had 
Wolf-Hirschhorn syndrome 
Self-limited familial infantile epilepsy 1 ϯ Had a causative PRRT2 gene variant 
Febrile seizures plus 2  
West syndrome 1  
Other early infantile-onset DEE 1ϯ ϯ Had causative ALG3 gene variants 
Febrile status 1  
NMDAR Total number 2  
 Syndrome classification  
Unclassified epilepsy 1* * Also positive for GABABR 
AMPAR Total number 0  
GlyR Total number 3  
 Syndrome classification  
Myoclonic epilepsy of infancy 1  
Unclassified myoclonic epilepsy 1ϯ ϯ Had causative SLC2A1 variant 












Odd’s ratio for antibody 
positivity [95% confidence 




Total cohort 18/298 (6.0%) 
Age of first seizure  
< 6 months 4/70 (5.7%) 0.93 [0.29-2.9] n.s. 
6-12 months 5/75 (6.7%) 1.2 [0.40-3.4] n.s. 
12-18 months 7/63 (11.1%) 2.6 [0.98-7.2] n.s. 
18-24 months 1/40 (2.5%) 0.36 [0.047-2.8] n.s. 
24-30 months 0/21 (0.0%) Not calculable n.s. 
30-36 months 1/29 (3.4%) 0.53 [0.068-4.1] n.s. 
Type of first seizure  
Febrile generalised (not including 
status) 
2/37 (5.4%) 0.88 [0.19-4.0] n.s. 
Febrile focal (not including status) 0/7 (0.0%) Not calculable n.s. 
Febrile status (generalised or focal) 3/44 (6.8%) 1.2 [0.32-4.2] n.s. 
Afebrile focal (not including status) 6/73 (8.2%) 1.6 [0.57-4.4] n.s. 
Afebrile status (generalised or focal) 1/20 (5.0%) 0.81 [0.10-6.4] n.s. 
Afebrile unclassified 0/3 (0.0%) Not calculable n.s. 
Infantile spasms 2/21 (9.5%) 1.7 [0.37-8.0] n.s. 
Afebrile generalised (not including 
status) ¥ 
4/93 (4.3%) 0.61 [0.20-1.9] n.s. 
Afebrile generalised tonic-clonic 1/47 (2.1%) 0.30 [0.039-2.3] n.s. 
Afebrile generalised myoclonic 2/21 (9.5%) 1.7 [0.37-8.0] n.s. 
Afebrile generalised tonic 1/9 (11.1%) 2.0 [0.24-17] n.s. 
Afebrile generalised atonic 0/3 (0.0%) Not calculable n.s. 
Afebrile generalised absence 0/12 (0.0%) Not calculable n.s. 
Findings at 24 month follow-up  
Genetic aetiology identified 5/69 (7.2%) 1.3 [0.45-3.8] n.s. 
Structural aetiology identified 0/15 (0.0%) Not calculable n.s. 
Epilepsy diagnosed 16/228 (7.0%) 2.6 [0.58-11] n.s. 
Global developmental delay 8/87 (9.2%) 2.0 [0.78-5.3] n.s. 
Drug-resistant epilepsy 4/63 (6.3%) 1.1 [0.34-3.4] n.s. 
¥ Composite group including all generalised seizure types, with subgroups listed in the subsequent 
five rows 
* Numbers rounded to two significant figures 
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